Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083343
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2004-05-20
Brief Title:
Caspofungin for the Treatment of Non-blood Candida Infections 0991-045
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Open Noncomparative Study to Estimate the Safety Tolerability and Efficacy of Caspofungin Acetate in the Treatment of Adults With Invasive Candida Infections Excluding Patients With Candidemia as the Sole Site of Infection
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Candida is the most common fungal pathogen identified in hospitalized patients This study will seek to enroll adult patients 18 years of age or older with invasive Candida infections involving deep tissues and organs The study will not enroll patients whose only site of Candida infection was the bloodstream Patients that fulfill all study entry criteria will receive a single daily dose of caspofungin Caspofungin an intravenous echinocandin antifungal agent is already approved for the treatment of invasive candidiasis The dosage strength and duration of caspofungin will be individualized for each patient based on disease severity of disease and extent of infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_102 | None | None | None |
| Formerly-0404NBCI | None | None | None |
| MK0991-045 | None | None | None |